Savient Seeks Europe Partner For Gout Drug Krystexxa After CHMP Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
With other companies struggling to develop new gout therapies, Savient is hoping to develop a partnering strategy for Krystexxa in markets outside the U.S. as well as broaden use of the injectable biologic in different categories of patients.